Coverage

Montenegro: what the October 2026 FZOCG medicines list pays for in lung cancer

The medicines list of the FZOCG health insurance fund is available in its October 2026 version. We checked which lung cancer medicines it includes and who proposes the treatment.

  • Published on
  • Montenegro
  • Checked against the source by the hub team on 16 November 2026

Most important in brief

  • For EGFR, ALK and ROS1, tablets are on the list, including osimertinib, alectinib, brigatinib, lorlatinib and crizotinib.
  • Immunotherapy is on the list, including durvalumab after chemoradiotherapy in stage III.
  • No medicine for KRAS G12C, RET, MET or NTRK is on the list.
  • A tumour board proposes the treatment; usually two cycles are approved first.

What applies now

Medicines list of the FZOCG health insurance fund, October 2026 · List (PDF), all versions · checked on 16 November 2026

Test resultMedicineWhat for (simplified)
EGFR
osimertinib
First treatment with an EGFR mutation; with T790M; after complete surgery (stage IB–IIIA), up to 36 months.
EGFR
gefitinib
Advanced NSCLC with an EGFR mutation.
ALK
alectinib, brigatinib
First treatment or after crizotinib.
ALK
lorlatinib
First treatment or after earlier ALK tablets.
ALK, ROS1
crizotinib
For ALK (first treatment or later) and for ROS1.
no EGFR or ALK
pembrolizumab
First treatment: alone if PD-L1 is 50% or more, with chemotherapy if PD-L1 is lower. A few cycles first, then continued only if it works.
no EGFR or ALK
atezolizumab
First treatment alone if PD-L1 is high, or with chemotherapy; also after chemotherapy.
Stage III
durvalumab
After chemoradiotherapy for inoperable stage III, PD-L1 1% or more, up to 12 months.
Chemotherapy
carboplatin, cisplatin, docetaxel, paclitaxel, gemcitabine, vinorelbine, pemetrexed
On the list.

How to get the treatment

A tumour board proposes the treatment. Usually two cycles are approved first, then the effect is checked. The list names these tumour boards:

  • Klinički centar Crne Gore, Klinika za onkologiju i radioterapiju (Podgorica)
  • Opšta bolnica Bijelo Polje
  • Specijalna bolnica za plućne bolesti Brezovik (Nikšić)

Not on the list

Afatinib, erlotinib, amivantamab; no medicine against KRAS G12C, RET, MET or NTRK. Dabrafenib and trametinib are listed for melanoma only.

What this means for you

If you are treated in Montenegro, tablets for EGFR, ALK and ROS1 are on the list, and durvalumab after chemoradiotherapy in stage III. A tumour board proposes the treatment, usually for two cycles first.

For KRAS G12C, RET, MET and NTRK, no medicine is on the list. Ask your care team what other ways there are.

More under Costs

Sources

  1. FZOCG: Lista ljekova, oktobar 2026
  2. FZOCG: Lista ljekova, sve verzije

Source checked on 16 November 2026

All updates